ATE469644T1 - Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung - Google Patents

Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung

Info

Publication number
ATE469644T1
ATE469644T1 AT01982812T AT01982812T ATE469644T1 AT E469644 T1 ATE469644 T1 AT E469644T1 AT 01982812 T AT01982812 T AT 01982812T AT 01982812 T AT01982812 T AT 01982812T AT E469644 T1 ATE469644 T1 AT E469644T1
Authority
AT
Austria
Prior art keywords
polyethylene glycol
copolyvidone
coated
indenoä5
ethylupropionamide
Prior art date
Application number
AT01982812T
Other languages
English (en)
Inventor
Hajime Ishida
Makoto Fukuta
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE469644T1 publication Critical patent/ATE469644T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT01982812T 2000-11-17 2001-11-16 Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung ATE469644T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000351223 2000-11-17
PCT/JP2001/010016 WO2002040054A1 (en) 2000-11-17 2001-11-16 Pharmaceutical preparation containing copolyvidone

Publications (1)

Publication Number Publication Date
ATE469644T1 true ATE469644T1 (de) 2010-06-15

Family

ID=18824316

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01982812T ATE469644T1 (de) 2000-11-17 2001-11-16 Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung

Country Status (7)

Country Link
US (3) US20040018239A1 (de)
EP (2) EP1334732B1 (de)
AT (1) ATE469644T1 (de)
AU (1) AU2002214305A1 (de)
CA (2) CA2650698C (de)
DE (1) DE60142305D1 (de)
WO (1) WO2002040054A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
JP2004339162A (ja) * 2003-05-16 2004-12-02 Shin Etsu Chem Co Ltd 難溶性薬物を含む医薬用固形製剤とその製造方法
JP2006528182A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 薬学的製剤および酸に起因する消化器疾患の治療法
JP2006528181A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
TWI400220B (zh) 2004-09-13 2013-07-01 Takeda Pharmaceutical 光活性胺衍生物的製法
ES2366381T3 (es) * 2005-06-22 2011-10-19 Takeda Pharmaceutical Company Limited Comprimido que contiene un ingrediente activo difícilmente soluble.
TWI402261B (zh) * 2006-06-19 2013-07-21 Takeda Pharmaceutical 三環化合物及其醫藥組成物
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CN104546746A (zh) * 2013-10-28 2015-04-29 南京长澳医药科技有限公司 一种雷美替胺片剂及其制备工艺
US10931859B2 (en) 2016-05-23 2021-02-23 InSyte Systems Light emitter and sensors for detecting biologic characteristics
US10713458B2 (en) 2016-05-23 2020-07-14 InSyte Systems Integrated light emitting display and sensors for detecting biologic characteristics

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617328A1 (de) * 1966-07-28 1971-06-03 Knecht Adolf O Dr Neue,zuckerfreie UEberzuege fuer Tabletten und Drageekerne
JPS456558B1 (de) * 1966-12-21 1970-03-05
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
HUT54035A (en) * 1989-06-22 1991-01-28 Chinoin Gyogyszer Es Vegyeszet Process for coating labile pharmaceutical active components for protecting from oxygen and humidity
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5401562A (en) * 1992-03-27 1995-03-28 Fuji Photo Film Co., Ltd. Paper material for photosensitive materials and method of producing the same
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
CA2241666C (en) * 1996-03-08 2007-11-06 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
EP0971878B1 (de) * 1997-02-27 2008-03-26 Takeda Pharmaceutical Company Limited Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta
KR100517006B1 (ko) * 1997-04-28 2005-09-27 닛토덴코 가부시키가이샤 광학 활성 단량체를 포함하는 측쇄형 액정 중합체, 및 이를 포함하는 광학 소자
IL128043A (en) * 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
PL205145B1 (pl) * 1998-05-15 2010-03-31 Warner Lambert Co Trwała kompozycja stała zawierająca pochodną 4-amino-3-podstawionego kwasu butanowego oraz sposób jej wytwarzania
DE69910795T2 (de) * 1998-06-09 2004-06-17 Takeda Chemical Industries, Ltd. Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
DE19961897A1 (de) * 1999-12-20 2001-06-28 Basf Ag Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen
US6248359B1 (en) * 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent

Also Published As

Publication number Publication date
CA2650698C (en) 2013-05-28
WO2002040054A1 (en) 2002-05-23
EP1334732B1 (de) 2010-06-02
CA2650698A1 (en) 2002-05-23
DE60142305D1 (de) 2010-07-15
US20170020841A1 (en) 2017-01-26
EP1334732A1 (de) 2003-08-13
AU2002214305A1 (en) 2002-05-27
US20090274733A1 (en) 2009-11-05
US10098866B2 (en) 2018-10-16
EP1334732A4 (de) 2006-03-15
CA2428817C (en) 2010-06-01
EP2305219A1 (de) 2011-04-06
CA2428817A1 (en) 2002-05-23
US20040018239A1 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
DE60142305D1 (de) Pharmazeutische zubereitung enthaltend n-ä2-(1,6,7,8-tetrahydro-2h-indenoä5,4 büfuran-8-yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung
DE69832816D1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
ATE112961T1 (de) Cimetidin enthaltende arzneimittel.
NO20022998D0 (no) Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
DE60005819D1 (de) Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
DK136186A (da) Laegemiddelbaerer
DE69323442D1 (de) Flüssige pharmazeutische Formulierung mit verlängerter Wirkstoffabgabe
DE69638364D1 (de) Formulierungen mit kontrollierter abgabe (albuterol)
ATE80798T1 (de) Waessrige ueberzugsemulsion fuer pharmazeutische dosierungsformen.
DE60237372D1 (de) Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
DE69521924D1 (de) Pharmazeutische Darreichungsformen mit verzögerter Wirkstoffabgabe enthaltend Alfuzosinhydrochlorid
DE69811278D1 (de) Gegen magensaft geschützte omeprazol-mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen
AR029333A1 (es) Combinacion de drogas no interactivas , formulacion farmaceutica y paquete farmaceutico que comprende dicha combinacion y el uso de un inhibidor de la hmgcoa reductasa en la preparacion de un medicamento que se utiliza en terapia combinada
ATE85519T1 (de) Waesserige pharmazeutische ueberzuege fuer dosierformen.
DE69228674D1 (de) Nichtsteroide-entzündungshemmende Arzneimittel und Decongestirum enthaltende Augenarzneimittelzusammensetzung
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
NO20011217D0 (no) Doseringsform omfattende væskeformulering
DE59804823D1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
ATE290854T1 (de) Carbamazepinformulierung mit verzögerter freigabe
ATE304844T1 (de) Entzündungshemmende pharmazeutische formulierungen
EP1221926A4 (de) Pharmazeutische zusammensetzungen mit schlecht löslichen arzneimittelwirkstoffen
DE50003454D1 (de) Proteinenthaltende pharmazeutische zubereitung
DE69831940D1 (de) Tablette mit verlängerter Wirkstoffabgabe im Magen
ATE158172T1 (de) Pulverförmige pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties